Free Trial

Viracta Therapeutics (VIRX) Competitors

Viracta Therapeutics logo
$0.02 0.00 (-4.32%)
As of 03:47 PM Eastern

VIRX vs. QLGN, ONCO, JAGX, VRAX, PTN, AWH, APVO, PCSA, ALZN, and CDT

Should you be buying Viracta Therapeutics stock or one of its competitors? The main competitors of Viracta Therapeutics include Qualigen Therapeutics (QLGN), Onconetix (ONCO), Jaguar Animal Health (JAGX), Virax Biolabs Group (VRAX), Palatin Technologies (PTN), Aspira Women's Health (AWH), Aptevo Therapeutics (APVO), Heatwurx (PCSA), Alzamend Neuro (ALZN), and Conduit Pharmaceuticals (CDT). These companies are all part of the "pharmaceutical products" industry.

Viracta Therapeutics vs. Its Competitors

Qualigen Therapeutics (NASDAQ:QLGN) and Viracta Therapeutics (NASDAQ:VIRX) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their profitability, dividends, institutional ownership, earnings, risk, media sentiment, analyst recommendations and valuation.

In the previous week, Qualigen Therapeutics' average media sentiment score of 0.00 equaled Viracta Therapeutics'average media sentiment score.

Company Overall Sentiment
Qualigen Therapeutics Neutral
Viracta Therapeutics Neutral

Qualigen Therapeutics has a beta of 0.03, indicating that its stock price is 97% less volatile than the S&P 500. Comparatively, Viracta Therapeutics has a beta of 1.06, indicating that its stock price is 6% more volatile than the S&P 500.

Viracta Therapeutics has a consensus target price of $1.75, suggesting a potential upside of 11,190.32%. Given Viracta Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Viracta Therapeutics is more favorable than Qualigen Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Qualigen Therapeutics
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00
Viracta Therapeutics
0 Sell rating(s)
2 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.33

3.2% of Qualigen Therapeutics shares are held by institutional investors. Comparatively, 31.4% of Viracta Therapeutics shares are held by institutional investors. 1.8% of Qualigen Therapeutics shares are held by insiders. Comparatively, 10.7% of Viracta Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Qualigen Therapeutics has higher revenue and earnings than Viracta Therapeutics.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Qualigen Therapeutics$4.98M1.12-$6.26MN/AN/A
Viracta TherapeuticsN/AN/A-$51.06M-$1.10-0.01

Qualigen Therapeutics' return on equity of 0.00% beat Viracta Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Qualigen TherapeuticsN/A N/A N/A
Viracta Therapeutics N/A -1,899.61%-114.21%

Summary

Viracta Therapeutics beats Qualigen Therapeutics on 6 of the 10 factors compared between the two stocks.

Get Viracta Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for VIRX and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding VIRX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

VIRX vs. The Competition

MetricViracta TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ Exchange
Market Cap$616K$784.80M$5.53B$9.03B
Dividend YieldN/A4.84%5.24%4.01%
P/E Ratio-0.011.0919.3119.89
Price / SalesN/A230.50424.59117.07
Price / CashN/A23.4426.2128.59
Price / Book0.056.237.925.55
Net Income-$51.06M-$27.94M$3.17B$248.49M
7 Day PerformanceN/A2.21%2.18%5.37%
1 Month PerformanceN/A8.98%1.25%6.63%
1 Year PerformanceN/A11.57%33.90%21.20%

Viracta Therapeutics Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
VIRX
Viracta Therapeutics
2.1165 of 5 stars
$0.02
-4.3%
$1.75
+11,190.3%
-96.6%$616KN/A-0.0120Gap Down
QLGN
Qualigen Therapeutics
N/A$3.41
-3.9%
N/A-76.7%$2.61M$4.98M0.0050
ONCO
Onconetix
0.2903 of 5 stars
$4.77
-1.2%
N/A-99.1%$2.57M$2.52M0.0012Gap Down
JAGX
Jaguar Animal Health
1.8329 of 5 stars
$2.52
+0.8%
$60.00
+2,281.0%
-97.1%$2.55M$11.69M0.0050
VRAX
Virax Biolabs Group
2.837 of 5 stars
$0.79
+1.5%
$3.00
+278.9%
-29.1%$2.52M$160K0.005
PTN
Palatin Technologies
N/A$0.09
-44.6%
N/AN/A$2.45M$350K-0.0630Gap Down
High Trading Volume
AWH
Aspira Women's Health
0.9049 of 5 stars
$0.08
-12.5%
$5.50
+6,607.3%
-92.6%$2.44M$9.18M-0.07110High Trading Volume
APVO
Aptevo Therapeutics
2.0754 of 5 stars
$3.05
-1.0%
$219,040.00
+7,181,539.3%
-100.0%$2.33M$3.11M0.0050
PCSA
Heatwurx
3.6214 of 5 stars
$0.21
+4.5%
$2.00
+875.6%
-88.8%$2.33MN/A-0.0720Gap Up
ALZN
Alzamend Neuro
2.2367 of 5 stars
$2.91
+0.3%
$180.00
+6,085.6%
-91.6%$2.32MN/A0.004Positive News
Gap Up
CDT
Conduit Pharmaceuticals
0.1429 of 5 stars
$2.76
-4.2%
N/A-99.6%$2.30MN/A-0.013News Coverage
High Trading Volume

Related Companies and Tools


This page (NASDAQ:VIRX) was last updated on 7/7/2025 by MarketBeat.com Staff
From Our Partners